Azithromycin decreases Chlamydia pneumoniae-mediated Interleukin-4 responses but not Immunoglobulin E responses.
Aged
Anti-Bacterial Agents
/ pharmacology
Asthma
/ complications
Azithromycin
/ pharmacology
Chlamydophila Infections
/ complications
Chlamydophila pneumoniae
/ drug effects
Female
Humans
Hypersensitivity, Immediate
/ complications
Immunoglobulin E
/ biosynthesis
In Vitro Techniques
Interleukin-4
/ biosynthesis
Leukocytes, Mononuclear
/ drug effects
Male
Middle Aged
Respiratory Tract Infections
/ complications
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
05
2020
accepted:
24
05
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
29
8
2020
Statut:
epublish
Résumé
Chlamydia pneumoniae is an obligate intracellular bacterium that causes respiratory infection. There may exist an association between C. pneumoniae, asthma, and production of immunoglobulin (Ig) E responses in vitro. Interleukin (IL-4) is required for IgE production. We previously demonstrated that doxycycline suppresses C. pneumoniae-induced production of IgE and IL-4 responses in peripheral blood mononuclear cells (PBMC) from asthmatic subjects. Whereas macrolides have anti-chlamydial activity, their effect on in vitro anti-inflammatory (IgE) and IL-4 responses to C. pneumoniae have not been studied. PBMC from IgE- adult atopic subjects (N = 5) were infected +/- C. pneumoniae BAL69, +/- azithromycin (0.1, 1.0 ug/mL) for 10 days. IL-4 and IgE levels were determined in supernatants by ELISA. IL-4 and IgE were detected in supernatants of PBMC (day 10). When azithromycin (0.1, 1.0 ug/ml) was added, IL-4 levels decreased. At low dose, IgE levels increased and at high dose, IgE levels decreased. When PBMC were infected with C. pneumoniae, both IL-4 and IgE levels decreased. Addition of azithromycin (0.1, 1.0 ug/mL) decreased IL-4 levels and had no effect on IgE levels. These findings indicate that azithromycin decreases IL-4 responses but has a bimodal effect on IgE responses in PBMC from atopic patients in vitro.
Sections du résumé
BACKGROUND
Chlamydia pneumoniae is an obligate intracellular bacterium that causes respiratory infection. There may exist an association between C. pneumoniae, asthma, and production of immunoglobulin (Ig) E responses in vitro. Interleukin (IL-4) is required for IgE production.
OBJECTIVE
We previously demonstrated that doxycycline suppresses C. pneumoniae-induced production of IgE and IL-4 responses in peripheral blood mononuclear cells (PBMC) from asthmatic subjects. Whereas macrolides have anti-chlamydial activity, their effect on in vitro anti-inflammatory (IgE) and IL-4 responses to C. pneumoniae have not been studied.
METHODS
PBMC from IgE- adult atopic subjects (N = 5) were infected +/- C. pneumoniae BAL69, +/- azithromycin (0.1, 1.0 ug/mL) for 10 days. IL-4 and IgE levels were determined in supernatants by ELISA. IL-4 and IgE were detected in supernatants of PBMC (day 10).
RESULTS
When azithromycin (0.1, 1.0 ug/ml) was added, IL-4 levels decreased. At low dose, IgE levels increased and at high dose, IgE levels decreased. When PBMC were infected with C. pneumoniae, both IL-4 and IgE levels decreased. Addition of azithromycin (0.1, 1.0 ug/mL) decreased IL-4 levels and had no effect on IgE levels.
CONCLUSIONS
These findings indicate that azithromycin decreases IL-4 responses but has a bimodal effect on IgE responses in PBMC from atopic patients in vitro.
Identifiants
pubmed: 32511255
doi: 10.1371/journal.pone.0234413
pii: PONE-D-20-13964
pmc: PMC7279567
doi:
Substances chimiques
Anti-Bacterial Agents
0
IL4 protein, human
0
Interleukin-4
207137-56-2
Immunoglobulin E
37341-29-0
Azithromycin
83905-01-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0234413Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Allergy Clin Immunol. 2001 Apr;107(4):595-601
pubmed: 11295645
Expert Opin Pharmacother. 2015 Feb;16(2):205-12
pubmed: 25579069
J Asthma. 2007 Nov;44(9):711-5
pubmed: 17994399
Arch Pediatr Adolesc Med. 1994 Jul;148(7):727-32
pubmed: 8019629
J Clin Microbiol. 2003 Feb;41(2):592-600
pubmed: 12574252
J Infect Chemother. 2018 Jun;24(6):470-475
pubmed: 29615379
Am J Transplant. 2007 Jan;7(1):76-82
pubmed: 17061983
Kurume Med J. 2001;48(2):165-70
pubmed: 11501498
Cochrane Database Syst Rev. 2005 Oct 19;(4):CD002997
pubmed: 16235309
J Lab Clin Med. 2004 Jul;144(1):18-26
pubmed: 15252403
J Clin Microbiol. 1992 Aug;30(8):1968-71
pubmed: 1500500
J Clin Microbiol. 2001 Apr;39(4):1385-90
pubmed: 11283060
Int J Antimicrob Agents. 1999 Feb;11(2):121-32
pubmed: 10221415
J Antimicrob Chemother. 2013 Oct;68(10):2363-8
pubmed: 23749949
Clin Infect Dis. 1992 Jan;14(1):178-82
pubmed: 1571425
Allergy Asthma Proc. 2008 May-Jun;29(3):286-94
pubmed: 18534087
Am J Respir Crit Care Med. 2005 Nov 1;172(9):1078-89
pubmed: 15961690
Antimicrob Agents Chemother. 2002 Feb;46(2):409-12
pubmed: 11796350